LabGenius Therapeutics

LG Chem Partners with LabGenius: AI/ML-Driven Multispecific Antibody Development Reshapes Oncology Pipeline Strategy

LG Chem's multi-year collaboration with LabGenius Therapeutics for AI/ML-designed multispecific antibodies in oncology signals a strategic shift. This deal, involving preclinical research and potential triple-digit million milestones, underscores the increasing reliance on advanced computational platforms like EVA for accelerating drug discovery. Procurement and R&D leaders must assess AI's role in their future pipelines.